Our neutral summary
The FDA is assessing Moderna's mRNA-based flu vaccine, mFlusiva, which targets older Americans. The evaluation is taking place ahead of the winter flu season.
The reporting belongs to PBS NewsHour; we don't reproduce it.
14
Public broadcaster
L
R
No clear lean
✓ verified
Why this rating? · 1 signal
Signals flagged in the original
- framing: first-of-its-kind
Analyzed by our bias model Full breakdown ↓
FDA panel reviews Moderna's mRNA flu vaccine for older Americans
The FDA is assessing Moderna's mRNA-based flu vaccine, mFlusiva, which targets older Americans. The evaluation is taking place ahead of the winter flu season.
Companies
Moderna
Annotating as
No note attached
on this article.
Language Analysis
Loaded-language score
14/100
wirepublicmainstream
flavoredpartisanadvocacy
Inflammatory language
10/100
Loaded Language Removed
- ✕ framing: first-of-its-kind
Original vs. Neutral
Original Headline
FDA panel backs first-of-its-kind flu vaccine using mRNA technology
Neutral Headline
FDA panel reviews Moderna's mRNA flu vaccine for older Americans